Bile acids and their nuclear receptor FXR: Relevance for hepatobiliary and gastrointestinal disease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 7, 2010, Pages 683-692

  Gadaleta, Raffaella M ^a,b   van Mil, Saskia W C ^a   Oldenburg, Bas ^a   Siersema, Peter D ^a   Klomp, Leo W J ^a   van Erpecum, Karel J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Netherlands Metabolomics Center ^*  (Italy)

Author keywords

Bile acid; Carcinogenesis; Enterohepatic circulation; Farnesoid X Receptor; Inflammation

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 6 ETHYLCHENODEOXYCHOLIC ACID; BILE ACID; CARRIER PROTEIN; CHOLESTEROL; DEXTRAN SULFATE; FARNESOID X RECEPTOR; GUGGULSTERONE; LIVER PROTECTIVE AGENT; LIVER X RECEPTOR; MESSENGER RNA; PROTEIN ABCB11; PROTEIN ABCB4; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; WAY 362450;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BARRETT ESOPHAGUS; BILE ACID SYNTHESIS; CHOLESTASIS; CHOLESTEROL STONE; COLITIS; COLON CANCER; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; DRUG POTENCY; ENTERITIS; ENTEROHEPATIC CIRCULATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE MUTATION; HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; IN VITRO STUDY; INTESTINE METAPLASIA; INTRAHEPATIC CHOLESTASIS; INTRAHEPATIC CHOLESTASIS OF PREGNANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER REGENERATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; TOXIC HEPATITIS;

ANIMALS; BACTERIAL TRANSLOCATION; BILE; BILE ACIDS AND SALTS; GASTROINTESTINAL DISEASES; HUMANS; INTESTINES; LIVER; LIVER DISEASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REGENERATION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 77952673509     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.04.006     Document Type: Review

References (88)

1. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., and Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7 (2008) 678-693
2. Zhang S., Liu Q., Wang J., and Harnish D.C. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem. Biophys. Res. Commun. 379 (2009) 476-479
3. Gerloff T., Stieger B., Hagenbuch B., Madon J., Landmann L., Roth J., Hofmann A.F., and Meier P.J. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J. Biol. Chem. 273 (1998) 10046-10050
4. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., Kwiterovich P., Shan B., Barnes R., and Hobbs H.H. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290 (2000) 1771-1775
5. Smit J.J.M., Schinkel A.H., Oude Elferink R.P.J., Groen A.K., Wagenaar E., van Deemter L., Mol C.A.A., Ottenhoff R., van der Lugt N.M.T., van Roon M.A., Offerhaus G.J.A., Berns A.J.M., and Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75 (1993) 451-462
6. Moschetta A., vanBerge-Henegouwen G.P., Portincasa P., Palasciano G., Groen A.K., and van Erpecum K.J. Sphingomyelin exhibits greatly enhanced protection compared with egg yolk phosphatidylcholine against detergent bile salts. J. Lipid Res. 41 (2000) 916-924
7. Ujhazy P., Ortiz D., Misra S., Li S., Moseley J., Jones H., and Arias I.M. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 34 (2001) 768-775
8. van Erpecum K.J., and Carey M.C. Influence of bile salts on molecular interactions between sphingomyelin and cholesterol: relevance to bile formation and stability. Biochim. Biophys. Acta 1345 (1997) 269-282
9. Nibbering C.P., Groen A.K., Ottenhoff R., Brouwers J.F., vanBerge-Henegouwen G.P., and van Erpecum K.J. Regulation of biliary cholesterol secretion is independent of hepatocyte canalicular membrane lipid composition: a study in the diosgenin-fed rat model. J. Hepatol. 35 (2001) 164-169
10. Amigo L., Mendoza H., Zanlungo S., Miquel J.F., Rigotti A., Gonzalez S., and Nervi F. Enrichment of canalicular membrane with cholesterol and sphingomyelin prevents bile salt-induced hepatic damage. J. Lipid Res. 40 (1999) 533-542
11. Ismair M.G., Hausler S., Stuermer C.A., Guyot C., Meier P.J., Roth J., and Stieger B. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49 (2009) 1673-1682
12. van Erpecum K.J. Biliary lipids, water and cholesterol gallstones. Biol. Cell 97 (2005) 815-822
13. lo Sasso S.G., Petruzzelli M., and Moschetta A. A translational view on the biliary lipid secretory network. Biochim. Biophys. Acta 1781 (2008) 79-96
14. Wong M.H., Oelkers P., and Dawson P.A. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. J. Biol. Chem. 270 (1995) 27228-27234
15. Choi M., Moschetta A., Bookout A.L., Peng L., Umetani M., Holmstrom S.R., Suino-Powell K., Xu H.E., Richardson J.A., Gerard R.D., Mangelsdorf D.J., and Kliewer S.A. Identification of a hormonal basis for gallbladder filling. Nat. Med. 12 (2006) 1253-1255
16. Dawson P.A., Hubbert M., Haywood J., Craddock A.L., Zerangue N., Christian W.V., and Ballatori N. The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter. J. Biol. Chem. 280 (2005) 6960-6968
17. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., and Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81 (1995) 687-693
18. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., and Shan B. Identification of a nuclear receptor for bile acids. Science 284 (1999) 1362-1365
19. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., Stimmel J.B., Willson T.M., Zavacki A.M., Moore D.D., and Lehmann J.M. Bile acids: natural ligands for an orphan nuclear receptor. Science 284 (1999) 1365-1368
20. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., and Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31 (2006) 572-580
21. Modica S., and Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?. FEBS Lett. 580 (2006) 5492-5499
22. Jung D., Hagenbuch B., Fried M., Meier P.J., and Kullak-Ublick G.A. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G752-G761
23. Denson L.A., Auld K.L., Schiek D.S., McClure M.H., Mangelsdorf D.J., and Karpen S.J. Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation. J. Biol. Chem. 275 (2000) 8835-8843
24. Denson L.A., Sturm E., Echevarria W., Zimmerman T.L., Makishima M., Mangelsdorf D.J., and Karpen S.J. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology 121 (2001) 140-147
25. Gartung C., Ananthanarayanan M., Rahman M.A., Schuele S., Nundy S., Soroka C.J., Stolz A., Suchy F.J., and Boyer J.L. Down-regulation of expression and function of the rat liver Na+/bile acid cotransporter in extrahepatic cholestasis. Gastroenterology 110 (1996) 199-209
26. Chen F., Ma L., Dawson P.A., Sinal C.J., Sehayek E., Gonzalez F.J., Breslow J., Ananthanarayanan M., and Shneider B.L. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278 (2003) 19909-19916
27. Neimark E., Chen F., Li X., and Shneider B.L. Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40 (2004) 149-156
28. Schaap F.G., van der Gaag N.A., Gouma D.J., and Jansen P.L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 49 (2009) 1228-1235
29. Zollner G., Marschall H.U., Wagner M., and Trauner M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol. Pharm. 3 (2006) 231-251
30. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B., and Jones S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 112 (2003) 1678-1687
31. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., Sabatino G., Russo G., Castellani D., Willson T.M., Pruzanski M., Pellicciari R., and Morelli A. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J. Pharmacol. Exp. Ther. 313 (2005) 604-612
32. Paulusma C.C., Groen A., Kunne C., Ho-Mok K.S., Spijkerboer A.L., de Waart R., Hoek F.J., Vreeling H., Hoeben K.A., van Marle J., Pawlikowska L., Bull L.N., Hofmann A.F., Knisely A.S., and Oude Elferink R.P. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44 (2006) 195-204
33. Groen A., Kunne C., Jongsma G., van den Oever K., Mok K.S., Petruzzelli M., Vrins C.L., Bull L., Paulusma C.C., and Oude Elferink R.P. Abcg5/8 independent biliary cholesterol excretion in Atp8b1-deficient mice. Gastroenterology 134 (2008) 2091-2100
34. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., Venneman N.G., Schwartz T.P., van Berge Henegouwen G.P., Devlin J., van Nieuwkerk C.M., Knisely A.S., and Houwen R.H. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 43 (2006) 51-53
35. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., Klomp L.W., Lomri N., Berger R., Scharschmidt B.F., Knisely A.S., Houwen R.H., and Freimer N.B. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat. Genet. 18 (1998) 219-224
36. Pawlikowska L., Groen A., Eppens E.F., Kunne C., Ottenhoff R., Looije N., Knisely A.S., Killeen N.P., Bull L.N., Oude Elferink R.P., and Freimer N.B. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum. Mol. Genet. 13 (2004) 881-892
37. Chen F., Ananthanarayanan M., Emre S., Neimark E., Bull L.N., Knisely A.S., Strautnieks S.S., Thompson R.J., Magid M.S., Gordon R., Balasubramanian N., Suchy F.J., and Shneider B.L. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126 (2004) 756-764
38. Frankenberg T., Miloh T., Chen F.Y., Ananthanarayanan M., Sun A.Q., Balasubramaniyan N., Arias I., Setchell K.D., Suchy F.J., and Shneider B.L. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48 (2008) 1896-1905
39. Alvarez L., Jara P., Sanchez-Sabate E., Hierro L., Larrauri J., Diaz M.C., Camarena C., de la Vega A., Frauca E., Lopez-Collazo E., and Lapunzina P. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum. Mol. Genet. 13 (2004) 2451-2460
40. Martinez-Fernandez P., Hierro L., Jara P., and Alvarez L. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064. Am. J. Physiol. Gastrointest. Liver Physiol. 296 (2009) G1119-G1129
41. Cai S.Y., Gautam S., Nguyen T., Soroka C.J., Rahner C., and Boyer J.L. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 136 (2009) 1060-1069
42. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., and Houwen R.H. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52 (2010) 258-271
43. Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R., Kullak-Ublick G.A., Meier P.J., and Pauli-Magnus C. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics 17 (2007) 47-60
44. van Mil S.W., Milona A., Dixon P.H., Mullenbach R., Geenes V.L., Chambers J., Shevchuk V., Moore G.E., Lammert F., Glantz A.G., Mattsson L.A., Whittaker J., Parker M.G., White R., and Williamson C. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133 (2007) 507-516
45. Chignard N., and Poupon R. Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases. Gastroenterology 137 (2009) 734-735
46. Chignard N., Mergey M., Barbu V., Finzi L., Tiret E., Paul A., and Housset C. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Hepatology 42 (2005) 549-557
47. D'Aldebert E., Biyeyeme Bi Mve M.J., Mergey M., Wendum D., Firrincieli D., Coilly A., Fouassier L., Corpechot C., Poupon R., Housset C., and Chignard N. Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 136 (2009) 1435-1443
48. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Weiglein A.H., Lammert F., Marschall H.U., Tsybrovskyy O., Zatloukal K., Denk H., and Trauner M. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 123 (2002) 1238-1251
49. Wagner M., Fickert P., Zollner G., Fuchsbichler A., Silbert D., Tsybrovskyy O., Zatloukal K., Guo G.L., Schuetz J.D., Gonzalez F.J., Marschall H.U., Denk H., and Trauner M. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125 (2003) 825-838
50. Moschetta A., Bookout A.L., and Mangelsdorf D.J. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat. Med. 10 (2004) 1352-1358
51. Bergheim I., Harsch S., Mueller O., Schimmel S., Fritz P., and Stange E.F. Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J. Lipid Res. 47 (2006) 42-50
52. Renner O., Harsch S., Strohmeyer A., Schimmel S., and Stange E.F. Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J. Lipid Res. 49 (2008) 2045-2054
53. Galman C., Miquel J.F., Perez R.M., Einarsson C., Stahle L., Marshall G., Nervi F., and Rudling M. Bile acid synthesis is increased in Chilean Hispanics with gallstones and in gallstone high-risk Mapuche Indians. Gastroenterology 126 (2004) 741-748
54. Kovacs P., Kress R., Rocha J., Kurtz U., Miquel J.F., Nervi F., Mendez-Sanchez N., Uribe M., Bock H.H., Schirin-Sokhan R., Stumvoll M., Mossner J., Lammert F., and Wittenburg H. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J. Hepatol. 48 (2008) 116-124
55. Yang F., Huang X., Yi T., Yen Y., Moore D.D., and Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67 (2007) 863-867
56. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., and Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48 (2008) 1632-1643
57. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (2006) S99-S112
58. Cipriani S., Mencarelli A., Palladino G., and Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51 (2010) 771-784
59. Sanyal A.J., Mudaliar S., Henry R.R., Marchall H., Morrow L., Sciacca C.I., Dillon P., Clopton P., Kipnes M., and Shapiro D. A new therapy for nonalcoholic fatty liver disease and diabetes? INT 747 - the first FXR hepatic therapeutic study. Hepatology 50 (2009) 389-390
60. Kong B., Luyendyk J.P., Tawfik O., and Guo G.L. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 328 (2009) 116-122
61. Zhang S., Wang J., Liu Q., and Harnish D.C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51 (2009) 380-388
62. Mencarelli A., Renga B., Migliorati M., Cipriani S., Distrutti E., Santucci L., and Fiorucci S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J. Immunol. 183 (2009) 6657-6666
63. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Morelli A., Pruzanski M., and Pellicciari R. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J. Pharmacol. Exp. Ther. 315 (2005) 58-68
64. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., and Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
65. Fickert P., Fuchsbichler A., Moustafa T., Wagner M., Zollner G., Halilbasic E., Stoger U., Arrese M., Pizarro M., Solis N., Carrasco G., Caligiuri A., Sombetzki M., Reisinger E., Tsybrovskyy O., Zatloukal K., Denk H., Jaeschke H., Pinzani M., and Trauner M. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol. 175 (2009) 2392-2405
66. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., and Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006) 233-236
67. Milona A., Owen B.M., van Mil S., Dormann D., Mataki C., Boudjelal M., Cairns W., Schoonjans K., Milligan S., Parker M., White R., and Williamson C. The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr. Am. J. Physiol. Gastrointest. Liver Physiol. 298 (2010) G151-G158
68. Chen W.D., Wang Y.D., Zhang L., Shiah S., Wang M., Yang F., Yu D., Forman B.M., and Huang W. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 51 (2010) 953-962
69. Wolfe A., Guo G.L., and Apte U. Sustained activation of WNT/B-catenin pathway as a mechanism behind spontaneous hepatocellular carcinoma in FXR knockout mice. Hepatology 50 (2009) 857
70. Abraham C., and Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 361 (2009) 2066-2078
71. Sung J.Y., Shaffer E.A., and Costerton J.W. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Dig. Dis. Sci. 38 (1993) 2104-2112
72. Inagaki T., Moschetta A., Lee Y.K., Peng L., Zhao G., Downes M., Yu R.T., Shelton J.M., Richardson J.A., Repa J.J., Mangelsdorf D.J., and Kliewer S.A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3920-3925
73. Vavassori P., Mencarelli A., Renga B., Distrutti E., and Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183 (2009) 6251-6261
74. de Gottardi A., Touri F., Maurer C.A., Perez A., Maurhofer O., Ventre G., Bentzen C.L., Niesor E.J., and Dufour J.F. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig. Dis. Sci. 49 (2004) 982-989
75. Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D., Gao X., Zhang Y., Ganapathy V., Gonzalez F.J., and Guo G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 328 (2009) 469-477
76. Modica S., Murzilli S., Salvatore L., Schmidt D.R., and Moschetta A. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res. 68 (2008) 9589-9594
77. Popivanova B.K., Kitamura K., Wu Y., Kondo T., Kagaya T., Kaneko S., Oshima M., Fujii C., and Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118 (2008) 560-570
78. Nehra D., Howell P., Williams C.P., Pye J.K., and Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 44 (1999) 598-602
79. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., Omary M.B., and Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 118 (2000) 487-496
80. Jenkins G.J., Harries K., Doak S.H., Wilmes A., Griffiths A.P., Baxter J.N., and Parry J.M. The bile acid deoxycholic acid (DCA) at neutral pH activates NF-kappaB and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 25 (2004) 317-323
81. Kazumori H., Ishihara S., Rumi M.A., Kadowaki Y., and Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55 (2006) 16-25
82. Tselepis C., Morris C.D., Wakelin D., Hardy R., Perry I., Luong Q.T., Harper E., Harrison R., Attwood S.E., and Jankowski J.A. Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 52 (2003) 174-180
83. de Gottardi A., Dumonceau J.M., Bruttin F., Vonlaufen A., Morard I., Spahr L., Rubbia-Brandt L., Frossard J.L., Dinjens W.N., Rabinovitch P.S., and Hadengue A. Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol. Cancer 5 (2006) 48
84. Capello A., Moons L.M., van de Winkel A., Siersema P.D., van Dekken H., Kuipers E.J., and Kusters J.G. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am. J. Gastroenterol. 103 (2008) 1510-1516
85. Dvorak K., Watts G.S., Ramsey L., Holubec H., Payne C.M., Bernstein C., Jenkins G.J., Sampliner R.E., Prasad A., Garewal H.S., and Bernstein H. Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma. Am. J. Gastroenterol. 104 (2009) 302-309
86. Zhou C., Tabb M.M., Nelson E.L., Grun F., Verma S., Sadatrafiei A., Lin M., Mallick S., Forman B.M., Thummel K.E., and Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116 (2006) 2280-2289
87. Kim M.S., Shigenaga J., Moser A., Feingold K., and Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 278 (2003) 8988-8995
88. Pascual G., and Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17 (2006) 321-327